Univariate analysis of risk factors for tumor regression and survival
. | . | Objective response . | . | 18-month overall survival . | . | ||
|---|---|---|---|---|---|---|---|
. | No. of evaluable cases . | Cumulative incidence, % (95% CI) . | P . | Probability, % (95% CI) . | P . | ||
| Diagnosis | NS | NS | |||||
| Renal cell carcinoma | 25 | 8 (0-19) | 20 (9-41) | ||||
| Breast carcinoma | 12 | 17 (0-38) | 28 (9-62) | ||||
| Ovarian carcinoma | 5 | 60 (17-100) | 30 (6-75) | ||||
| Melanoma | 5 | 20 (0-55) | 20 (3-62) | ||||
| Others | 10 | 0 | 0 | ||||
| Patient age | NS | NS | |||||
| Younger than 45 y | 30 | 13 (1-25) | 13 (4-34) | ||||
| Older than 45 y | 27 | 15 (2-28) | 25 (12-44) | ||||
| Donor sex | NS | .02 | |||||
| Female | 31 | 13 (1-25) | 6 (2-20) | ||||
| Male | 26 | 15 (1-29) | 40 (23-60) | ||||
| Disease status | .00005 | .0003 | |||||
| Progressive | 39 | 0 | 0 | ||||
| Stable | 18 | 44 (21-67) | 54 (32-74) | ||||
| Stem cell source | NS | NS | |||||
| Bone marrow | 16 | 6 (0-18) | 13 (4-36) | ||||
| Peripheral blood stem cell | 41 | 17 (6-28) | 23 (12-39) | ||||
| ATG dose infused during conditioning | NS | .02 | |||||
| 2.5 mg/kg | 40 | 18 (6-30) | 26 (14-43) | ||||
| 5-10 mg/kg | 17 | 6 (0-17) | 6 (1-27) | ||||
| Acute GVHD | NS | NS | |||||
| Grades 0-I | 33 | 12 (1-23) | 23 (11-42) | ||||
| Grades II-IV | 24 | 17 (2-32) | 14 (5-34) | ||||
| Chronic GVHD | NS | .05 | |||||
| No | 17 | 6 (0-18) | 21 (8-46) | ||||
| Yes | 25 | 28 (10-46) | 35 (13-51) | ||||
. | . | Objective response . | . | 18-month overall survival . | . | ||
|---|---|---|---|---|---|---|---|
. | No. of evaluable cases . | Cumulative incidence, % (95% CI) . | P . | Probability, % (95% CI) . | P . | ||
| Diagnosis | NS | NS | |||||
| Renal cell carcinoma | 25 | 8 (0-19) | 20 (9-41) | ||||
| Breast carcinoma | 12 | 17 (0-38) | 28 (9-62) | ||||
| Ovarian carcinoma | 5 | 60 (17-100) | 30 (6-75) | ||||
| Melanoma | 5 | 20 (0-55) | 20 (3-62) | ||||
| Others | 10 | 0 | 0 | ||||
| Patient age | NS | NS | |||||
| Younger than 45 y | 30 | 13 (1-25) | 13 (4-34) | ||||
| Older than 45 y | 27 | 15 (2-28) | 25 (12-44) | ||||
| Donor sex | NS | .02 | |||||
| Female | 31 | 13 (1-25) | 6 (2-20) | ||||
| Male | 26 | 15 (1-29) | 40 (23-60) | ||||
| Disease status | .00005 | .0003 | |||||
| Progressive | 39 | 0 | 0 | ||||
| Stable | 18 | 44 (21-67) | 54 (32-74) | ||||
| Stem cell source | NS | NS | |||||
| Bone marrow | 16 | 6 (0-18) | 13 (4-36) | ||||
| Peripheral blood stem cell | 41 | 17 (6-28) | 23 (12-39) | ||||
| ATG dose infused during conditioning | NS | .02 | |||||
| 2.5 mg/kg | 40 | 18 (6-30) | 26 (14-43) | ||||
| 5-10 mg/kg | 17 | 6 (0-17) | 6 (1-27) | ||||
| Acute GVHD | NS | NS | |||||
| Grades 0-I | 33 | 12 (1-23) | 23 (11-42) | ||||
| Grades II-IV | 24 | 17 (2-32) | 14 (5-34) | ||||
| Chronic GVHD | NS | .05 | |||||
| No | 17 | 6 (0-18) | 21 (8-46) | ||||
| Yes | 25 | 28 (10-46) | 35 (13-51) | ||||
NS indicates not significant.